Evaluating the Performance of Covidence's Artificial Intelligence-Based Screening Function in Cancer Systematic Reviews

Background

Systematic reviews (SRs), often conducted for evidence synthesis, require extensive multistage screening, with Stage-I title/abstract screening being especially time consuming. Covidence systematic review software, a widely used SR platform, has offered artificial intelligence (AI)-assisted Stage-I screening function since 2022. However, this function's performance has not yet been formally compared across heterogeneous, large-scale oncology-focused SRs.